Correlation Between Eledon Pharmaceuticals and NextCure

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eledon Pharmaceuticals and NextCure at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eledon Pharmaceuticals and NextCure into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eledon Pharmaceuticals and NextCure, you can compare the effects of market volatilities on Eledon Pharmaceuticals and NextCure and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eledon Pharmaceuticals with a short position of NextCure. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eledon Pharmaceuticals and NextCure.

Diversification Opportunities for Eledon Pharmaceuticals and NextCure

0.34
  Correlation Coefficient

Weak diversification

The 3 months correlation between Eledon and NextCure is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding Eledon Pharmaceuticals and NextCure in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NextCure and Eledon Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eledon Pharmaceuticals are associated (or correlated) with NextCure. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NextCure has no effect on the direction of Eledon Pharmaceuticals i.e., Eledon Pharmaceuticals and NextCure go up and down completely randomly.

Pair Corralation between Eledon Pharmaceuticals and NextCure

Given the investment horizon of 90 days Eledon Pharmaceuticals is expected to under-perform the NextCure. But the stock apears to be less risky and, when comparing its historical volatility, Eledon Pharmaceuticals is 1.33 times less risky than NextCure. The stock trades about -0.18 of its potential returns per unit of risk. The NextCure is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  77.00  in NextCure on December 4, 2024 and sell it today you would lose (3.00) from holding NextCure or give up 3.9% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Eledon Pharmaceuticals  vs.  NextCure

 Performance 
       Timeline  
Eledon Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Eledon Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
NextCure 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days NextCure has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Eledon Pharmaceuticals and NextCure Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eledon Pharmaceuticals and NextCure

The main advantage of trading using opposite Eledon Pharmaceuticals and NextCure positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eledon Pharmaceuticals position performs unexpectedly, NextCure can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NextCure will offset losses from the drop in NextCure's long position.
The idea behind Eledon Pharmaceuticals and NextCure pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Other Complementary Tools

Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance